Radioisotope Production (Iodine-123)

I-123 decays by electron capture and gamma emission with a half-life of 13.2 hours. It is typically produced in cyclotrons by bombarding xenon-124 with protons. The resulting I-123 is then chemically incorporated into radiopharmaceuticals. Supply chain considerations involve the availability of cyclotrons, xenon-124 targets, and radiochemistry facilities. Logistical challenges include the rapid transport and delivery of I-123 radiopharmaceuticals due to their relatively short half-life. Accessibility for developing countries is limited by the high cost and technical expertise required for production and handling.

I-123 production and application are well-established, with widespread use in nuclear medicine.

I-123 is a radioactive isotope that emits gamma rays, requiring careful handling and shielding to minimise radiation exposure.

While I-123 is not a proliferation concern, proper control and monitoring are necessary to prevent unauthorised access or misuse.

Traditional IAEA safeguards are not directly applicable due to the absence of fissile materials. However, monitoring and verification of the production and use of I-123 may be considered to ensure transparency and prevent misuse.